{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:40Z","timestamp":1707524320016},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,16]]},"DOI":"10.7759\/cureus.17236","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T06:13:07Z","timestamp":1629180787000},"source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of Stem Cell Therapies in Improving Clinical Outcomes in Patients With Heart Failure"],"prefix":"10.7759","author":[{"given":"Nitin","family":"Bhawnani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarthi","family":"Ethirajulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almothana","family":"Alkasabera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chike B","family":"Onyali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Comfort","family":"Anim-Koranteng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hira E","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihan A","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich PA","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA, et al.. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013, 6:606-19. 10.1161\/HHF.0b013e318291329a","journal-title":"Circ Heart Fail"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpa.2017.07.003","article-title":"Long-term management of end-stage heart failure","volume":"31","author":"Habal MV","year":"2017","unstructured":"Habal MV, Garan AR. Long-term management of end-stage heart failure. Best Pract Res Clin Anaesthesiol. 2017, 31:153-66. 10.1016\/j.bpa.2017.07.003","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"ref3","article-title":"Heart failure with preserved ejection fraction: Diagnosis and management","volume":"96","author":"Gazewood JD","year":"2017","unstructured":"Gazewood JD, Turner PL. Heart failure with preserved ejection fraction: Diagnosis and management. Am Fam Physician. 2017, 96:582-8.","journal-title":"Am Fam Physician"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1236","article-title":"Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Crespo-Leiro MG","year":"2018","unstructured":"Crespo-Leiro MG, Metra M, Lund LH, et al.. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018, 20:1505-35. 10.1002\/ejhf.1236","journal-title":"Eur J Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164680","article-title":"Evidence for cardiomyocyte renewal in humans","volume":"324","author":"Bergmann O","year":"2009","unstructured":"Bergmann O, Bhardwaj RD, Bernard S, et al.. Evidence for cardiomyocyte renewal in humans. Science. 2009, 324:98-102. 10.1126\/science.1164680","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000128597.37025.00","article-title":"Molecular and cell-based therapies for protection, rescue, and repair of ischemic myocardium: reasons for cautious optimism","volume":"109","author":"Melo LG","year":"2004","unstructured":"Melo LG, Pachori AS, Kong D, Gnecchi M, Wang K, Pratt RE, Dzau VJ. Molecular and cell-based therapies for protection, rescue, and repair of ischemic myocardium: reasons for cautious optimism. Circulation. 2004, 109:2386-93. 10.1161\/01.CIR.0000128597.37025.00","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-007-9047-9","article-title":"Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial stem cell therapy","volume":"13","author":"Vertesaljai M","year":"2008","unstructured":"Vertesaljai M, Piroth Z, Fontos G, et al.. Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial stem cell therapy. Heart Fail Rev. 2008, 13:227-44. 10.1007\/s10741-007-9047-9","journal-title":"Heart Fail Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1117","article-title":"Regenerating the heart","volume":"23","author":"Laflamme MA","year":"2005","unstructured":"Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol. 2005, 23:845-56. 10.1038\/nbt1117","journal-title":"Nat Biotechnol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn171","article-title":"Four-year follow-up of treatment with intramyocardial skeletal myoblasts injection in patients with ischaemic cardiomyopathy","volume":"29","author":"Veltman CE","year":"2008","unstructured":"Veltman CE, Soliman OI, Geleijnse ML, et al.. Four-year follow-up of treatment with intramyocardial skeletal myoblasts injection in patients with ischaemic cardiomyopathy. Eur Heart J. 2008, 29:1386-96. 10.1093\/eurheartj\/ehn171","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/ncpcardio1321","article-title":"Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone","volume":"5","author":"Ang KL","year":"2008","unstructured":"Ang KL, Chin D, Leyva F, et al.. Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone. Nat Clin Pract Cardiovasc Med. 2008, 5:663-70. 10.1038\/ncpcardio1321","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008460","article-title":"Comparison of mesenchymal stem cell efficacy in ischemic versus nonischemic dilated cardiomyopathy","volume":"7","author":"Tompkins BA","year":"2018","unstructured":"Tompkins BA, Rieger AC, Florea V, et al.. Comparison of mesenchymal stem cell efficacy in ischemic versus nonischemic dilated cardiomyopathy. J Am Heart Assoc. 2018, 7:e008460. 10.1161\/JAHA.117.008460","journal-title":"J Am Heart Assoc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.310712","article-title":"Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1\/2 randomized controlled trial (RIMECARD trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy])","volume":"121","author":"Bartolucci J","year":"2017","unstructured":"Bartolucci J, Verdugo FJ, Gonz\u00e1lez PL, et al.. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1\/2 randomized controlled trial (RIMECARD trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). Circ Res. 2017, 121:1192-204. 10.1161\/CIRCRESAHA.117.310712","journal-title":"Circ Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1700","article-title":"Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial","volume":"22","author":"Mathiasen AB","year":"2020","unstructured":"Mathiasen AB, Qayyum AA, J\u00f8rgensen E, et al.. Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial. Eur J Heart Fail. 2020, 22:884-92. 10.1002\/ejhf.1700","journal-title":"Eur J Heart Fail"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv390","article-title":"Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial","volume":"36","author":"Hamshere S","year":"2015","unstructured":"Hamshere S, Arnous S, Choudhury T, et al.. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. Eur Heart J. 2015, 36:3061-9. 10.1093\/eurheartj\/ehv390","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jocs.14454","article-title":"Combined transepicardial and transseptal implantation of autologous CD 133+ bone marrow cells during bypass grafting improves cardiac function in patients with low ejection fraction","volume":"35","author":"Soetisna TW","year":"2020","unstructured":"Soetisna TW, Sukmawan R, Setianto B, Mansyur M, Murni TW, Listiyaningsih E, Santoso A. Combined transepicardial and transseptal implantation of autologous CD 133+ bone marrow cells during bypass grafting improves cardiac function in patients with low ejection fraction. J Card Surg. 2020, 35:740-6. 10.1111\/jocs.14454","journal-title":"J Card Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah KS","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, et al.. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017, 70:2476-86. 10.1016\/j.jacc.2017.08.074","journal-title":"J Am Coll Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/hc0102.101442","article-title":"Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart","volume":"105","author":"Toma C","year":"2002","unstructured":"Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002, 105:93-8. 10.1161\/hc0102.101442","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.071","article-title":"Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics","volume":"61","author":"Bartunek J","year":"2013","unstructured":"Bartunek J, Behfar A, Dolatabadi D, et al.. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013, 61:2329-38. 10.1016\/j.jacc.2013.02.071","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4238\/2015.April.10.11","article-title":"Clinical observation of umbilical cord mesenchymal stem cell treatment of severe systolic heart failure","volume":"14","author":"Zhao XF","year":"2015","unstructured":"Zhao XF, Xu Y, Zhu ZY, Gao CY, Shi YN. Clinical observation of umbilical cord mesenchymal stem cell treatment of severe systolic heart failure. Genet Mol Res. 2015, 14:3010-7. 10.4238\/2015.April.10.11","journal-title":"Genet Mol Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.282909","article-title":"Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial","volume":"311","author":"Heldman AW","year":"2014","unstructured":"Heldman AW, DiFede DL, Fishman JE, et al.. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014, 311:62-73. 10.1001\/jama.2013.282909","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.25321","article-title":"Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial","volume":"308","author":"Hare JM","year":"2012","unstructured":"Hare JM, Fishman JE, Gerstenblith G, et al.. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012, 308:2369-79. 10.1001\/jama.2012.25321","journal-title":"JAMA"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.009","article-title":"Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic Dilated Cardiomyopathy: POSEIDON-DCM trial","volume":"69","author":"Hare JM","year":"2017","unstructured":"Hare JM, DiFede DL, Rieger AC, et al.. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic Dilated Cardiomyopathy: POSEIDON-DCM trial. J Am Coll Cardiol. 2017, 69:526-37. 10.1016\/j.jacc.2016.11.009","journal-title":"J Am Coll Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.03.066","article-title":"Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction","volume":"56","author":"Behfar A","year":"2010","unstructured":"Behfar A, Yamada S, Crespo-Diaz R, et al.. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol. 2010, 56:721-34. 10.1016\/j.jacc.2010.03.066","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv477","article-title":"Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study)","volume":"36","author":"Martino H","year":"2015","unstructured":"Martino H, Brofman P, Greco O, et al.. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). Eur Heart J. 2015, 36:2898-904. 10.1093\/eurheartj\/ehv477","journal-title":"Eur Heart J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.17-0197","article-title":"CD34+ cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy","volume":"7","author":"Frljak S","year":"2018","unstructured":"Frljak S, Jaklic M, Zemljic G, Cerar A, Poglajen G, Vrtovec B. CD34+ cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy. Stem Cells Transl Med. 2018, 7:168-72. 10.1002\/sctm.17-0197","journal-title":"Stem Cells Transl Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000147315.71699.51","article-title":"Isolation and expansion of adult cardiac stem cells from human and murine heart","volume":"95","author":"Messina E","year":"2004","unstructured":"Messina E, De Angelis L, Frati G, et al.. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004, 95:911-21. 10.1161\/01.RES.0000147315.71699.51","journal-title":"Circ Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.312311","article-title":"Impact of cardiac progenitor cells on heart failure and survival in single ventricle congenital heart disease","volume":"122","author":"Sano T","year":"2018","unstructured":"Sano T, Ousaka D, Goto T, et al.. Impact of cardiac progenitor cells on heart failure and survival in single ventricle congenital heart disease. Circ Res. 2018, 122:994-1005. 10.1161\/CIRCRESAHA.117.312311","journal-title":"Circ Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa541","article-title":"Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial","volume":"41","author":"Makkar RR","year":"2020","unstructured":"Makkar RR, Kereiakes DJ, Aguirre F, et al.. Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2020, 41:3451-8. 10.1093\/eurheartj\/ehaa541","journal-title":"Eur Heart J"},{"key":"ref29","doi-asserted-by":"crossref","DOI":"10.4244\/EIJV6I7A139","article-title":"Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial","volume":"6","author":"Duckers HJ","year":"2011","unstructured":"Duckers HJ, Houtgraaf J, Hehrlein C, et al.. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention. 2011, 6:805-12.","journal-title":"EuroIntervention"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-15-0243","article-title":"Safety and efficacy of autologous skeletal myoblast sheets (TCD-51073) for the treatment of severe chronic heart failure due to ischemic heart disease","volume":"79","author":"Sawa Y","year":"2015","unstructured":"Sawa Y, Yoshikawa Y, Toda K, et al.. Safety and efficacy of autologous skeletal myoblast sheets (TCD-51073) for the treatment of severe chronic heart failure due to ischemic heart disease. Circ J. 2015, 79:991-9. 10.1253\/circj.CJ-15-0243","journal-title":"Circ J"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.700","article-title":"Safety, feasibility and effectiveness of first in-human administration of muscle-derived stem\/progenitor cells modified with connexin-43 gene for treatment of advanced chronic heart failure","volume":"19","author":"Gwizdala A","year":"2017","unstructured":"Gwizdala A, Rozwadowska N, Kolanowski TJ, et al.. Safety, feasibility and effectiveness of first in-human administration of muscle-derived stem\/progenitor cells modified with connexin-43 gene for treatment of advanced chronic heart failure. Eur J Heart Fail. 2017, 19:148-57. 10.1002\/ejhf.700","journal-title":"Eur J Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/65375-effectiveness-of-stem-cell-therapies-in-improving-clinical-outcomes-in-patients-with-heart-failure","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:51Z","timestamp":1707507231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/65375-effectiveness-of-stem-cell-therapies-in-improving-clinical-outcomes-in-patients-with-heart-failure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.17236","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,16]]}}}